| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8004 | AZD6482 Featured | AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. |
|
| DC8468 | AZD-6738 Featured | AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2. |
|
| DC20731 | AZD-7325 Featured | AZD-7325 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 9.51. |
|
| DC12490 | AZD7507 Featured | AZD7507 (AZD-7507) is a potent, selective, orally available CSF-1R (c-FMS) with IC50 of 32 nM. |
|
| DC8837 | AZD-7547 Featured | AZD7545 is a novel, selective small-molecule inhibitor of PDHK2 (PDH kinase2) with an IC50 of 36.8 nM and 6.4 nM for PDHK1 and PDHK2 respectively. |
|
| DC20714 | AZD-7594 Featured | AZD-7594 (AZ-13189620) is a potent, nonsteroidal, selective glucocorticoid receptor modulator (SGRM) with binding IC50 of 0.9 nM, shows no affinity for AR, PR, MR and ERα/β. |
|
| DC20242 | AZD-7624 Featured | AZD-7624 a potent, selective, inhaled p38α MAPK inhibitor for the treatment of chronic obstructive pulmonary disease. |
|
| DC20278 | AZD-7648 Featured | AZD-7648 is a potent and selective DNA-PK inhibitor. AZD7648,enhances HDR efficiency in CRISPR-Cas9 gene editing by shifting DNA repair from the error-prone NHEJ pathway to the precise HDR pathway, significantly improving gene targeting outcomes in human cells for effective ex vivo gene therapies. |
|
| DC7076 | AZD-7762 Featured | AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM; equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. |
|
| DC11723 | AZD-7986(Brensocatib) Featured | AZD-7986(Brensocatib) is a highly potent, reversible, and selective DPP1 inhibitor with enzyme and cell pIC50 of 8.4. |
|
| DC5084 | AZD-8055 Featured | AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. |
|
| DC20733 | AZD-8165 | AZD-8165 is a potent, selective and oral thrombin inhibitor for treatment of thrombosis.. |
|
| DC8380 | AZD8186 Featured | AZD8186 is an inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. |
|
| DC20734 | AZD-8309 | AZD-8309 (AZD8309) is a potent and orally bioavailable CXCR2 antagonist that has been proposed to regulate the transmigration of neutrophils. |
|
| DC20735 | AZD 8329 | AZD8329 is a potent, selective 11β-HSD1 inhibitor with IC50 of 9 nM, displays excellent selectivity versus relatedd 11β-HSD2, 17β-HSD1 and 17β-HSD3 (IC50>30 uM). |
|
| DC7077 | AZD8330(ARRY-424704; ARRY-704) Featured | AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. |
|
| DC23437 | AZD-8529 Featured | AZD8529 is a novel potent, selective mGluR2 positive allosteric modulator with EC50 of 195 nM, does not produce any positive allosteric modulator responses for mGluR1 and 3-8 subtypes. |
|
| DC23408 | AZD-8529 mesylate Featured | AZD8529 is a novel potent, selective mGluR2 positive allosteric modulator with EC50 of 195 nM, does not produce any positive allosteric modulator responses for mGluR1 and 3-8 subtypes. |
|
| DC10202 | AZD8797 Featured | AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor; antagonizes CX3CL1 with IC50 values of 6 and 300 nM in B-lymphocyte cell line and human whole blood, respectively. |
|
| DC9879 | AZD8835 Featured | AZD8835 ia a novel mixed inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity against PI3Kβ (IC50=431 nM) and PI3Kγ (IC50=90 nM). |
|
| DC10425 | AZD9056 hydrochloride | AZD9056 is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases. |
|
| DC7006 | AZD-9291(Osimertinib) Featured | AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
|
| DC8462 | AZD-9291 mesylate (Osimertinib，Mereletinib) Featured | AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
|
| DC10112 | AZD9362 | AZD-9362 is dual IGF-IR/InsR inhibitor. |
|
| DC9268 | AZD9496 Featured | AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator(Ki=0.7 nM) and antagonist. |
|
| DC11541 | AZD-9567 | AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis.. |
|
| DC11542 | AZD-9567 monohydrate | AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis.. |
|
| DC20737 | AZD-9819 | AZD-9819 is an inhibitor of human neutrophil elastase for potential treatment of chronic obstructive pulmonary disease.. |
|
| DC11032 | AZD9977 Featured | AZD9977 is a first-in-class, potent, selective, mineralocorticoid receptor (MR) modulator with IC50 of 0.37. 0.08 and 0.08 uM for human, mouse and rat MR, respectively. |
|
| DC10245 | Azelaic acid | Azelaic acid is an organic compound produced by the ozonolysis of oleic acid and possesses antibacterial, keratolytic, comedolytic, and anti-oxidant activity. |
|
